11βOH-Progesterone Affects Vascular Glucocorticoid Metabolism and Contractile Response
- 1 September 1997
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 30 (3) , 449-454
- https://doi.org/10.1161/01.hyp.30.3.449
Abstract
Abstract Vascular smooth muscle (VSM) contains a bidirectional isoform of 11β-hydroxysteroid dehydrogenase (11β-HSD), the enzyme that can metabolize endogenous glucocorticoids to their respective 11-dehydro derivatives. 11βOH-progesterone (11βOH-P), a compound that can be produced in vivo, is as potent or more potent than licorice derivatives in inhibiting renal and hepatic 11β-HSD. When studied in homogenates prepared from primary cultures of rat VSM, 11βOH-P and its derivative, 11-keto-progesterone (11-keto-P), proved to be potent, directionally specific inhibitors of vascular 11β-HSD. 11βOH-P selectively inhibited the forward dehydrogenase reaction (corticosterone→11-dehydrocorticosterone), whereas 11-keto-P selectively blocked the reverse oxidoreductase reaction. To test the physiological effects, vascular rings were prepared from rat aorta. Rings were incubated in culture media containing either a submaximal concentration of corticosterone (10 nmol/L), 11-dehydrocorticosterone (100 nmol/L), 11βOH-P (1 μmol/L), 11-keto-P (1 μmol/L), or a combination of glucocorticoid and inhibitor for 24 hours. After the 24-hour incubation, rings were briefly stimulated sequentially with phenylephrine (10 nmol/L to 1 μmol/L) and angiotensin II (1 μmol/L). The immediate contractile response in rings incubated with both corticosterone and 11βOH-P was greater than in rings previously incubated with either the corticosterone or 11βOH-P alone (eg, response to 100 nmol/L phenylephrine in milligrams of force, mean±SE: corticosterone, 728±56, n=9; 11βOH-P, 325±105, n=4; both, 1132±122, n=8; corticosterone versus both, P <.01). In contrast, the immediate contractile responses to phenylephrine and to angiotensin II were attenuated in rings exposed previously to both 11-dehydrocorticosterone and 11-keto-P. Thus, 11βOH-P and 11-keto-P (and possibly structurally similar compounds) alter the vascular effects of glucocorticoids and may play a role in glucocorticoid-induced hypertension.Keywords
This publication has 16 references indexed in Scilit:
- Steroid hormones upregulate rat angiotensin II type 1A receptor gene: Role of glucocorticoid responsive elements in rat angiotensin II type 1A promoterThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Bidirectional activity of 11β-hydroxysteroid dehydrogenase in vascular smooth muscle cellsSteroids, 1995
- Glucocorticoids but not mineralocorticoids modulate endothelin-1 and angiotensin II binding in SHR vascular smooth muscle cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Mechanism of the effects of glucocorticoids and mineralocorticoids on vascular smooth muscle contractilitySteroids, 1993
- Inhibition of rat renal 11β-hydroxysteroid dehydrogenase by steroidal compounds and triterpenoids; structure/function relationshipBiochimica et Biophysica Acta (BBA) - General Subjects, 1991
- Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells.Journal of Clinical Investigation, 1991
- Glucocorticoids in Blood Pressure RegulationHormone Research, 1990
- The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volumeJournal Of Hypertension, 1989
- Corticosteroid 11β-hydroxysteroid dehydrogenase activities in vertebrate liverSteroids, 1988
- LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTORThe Lancet, 1988